Restricted accessResearch articleFirst published online 2016-10
Assays for Qualification and Quality Stratification of Clinical Biospecimens Used in Research: A Technical Report from the ISBER Biospecimen Science Working Group
This technical report presents quality control (QC) assays that can be performed in order to qualify clinical biospecimens that have been biobanked for use in research. Some QC assays are specific to a disease area. Some QC assays are specific to a particular downstream analytical platform. When such a qualification is not possible, QC assays are presented that can be performed to stratify clinical biospecimens according to their biomolecular quality.
Get full access to this article
View all access options for this article.
References
1.
CummingsJ, RaynaudF, JonesL, et al.Fit-for-purpose biomarker method validation for application in clinical trials of anticancer drugs. Br J Cancer, 2010; 103:1313–1317.
2.
BetsouF, BarnesR, BurkeT, et al.Human biospecimen research: experimental protocol and quality control tools. Cancer Epidemiol Biomarkers Prev, 2009; 18:1017–1025.
3.
LehmannS, GuadagniF, MooreH, et al.Standard preanalytical coding for biospecimens: review and implementation of the Sample PREanalytical Code (SPREC). Biopreserv Biobank, 2012; 10:366–374.
4.
SiestG, HennyJ, SchieleF. Références en Biologie Clinique. Paris: Elsévier; 1990.
5.
GhnassiaJ-C. Échantillons Biologiques Phase Préanalytique et Prélèvements en Biologie Médicale. Paris: Elsévier; 1998.
6.
BelenkyA, SmithA, ZhangB, et al.The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma. Clin Chim Acta, 2004; 340:163–172.
7.
WilliamsKM, WilliamsAE, KlineLM, et al.Stability of serum alanine aminotransferase activity. Transfusion, 1987; 27:431–433.
8.
GislefossRE, GrimsrudTK, MorkridL. Stability of selected serum proteins after long-term storage in the Janus Serum Bank. Clin Chem Lab Med, 2009; 47:596–603.
9.
KimW, EganJM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev, 2008; 60:470–512.
10.
RamontL, ThoannesH, VolondatA, et al.Effects of hemolysis and storage condition on neuron-specific enolase (NSE) in cerebrospinal fluid and serum: implications in clinical practice. Clin Chem Lab Med, 2005; 43:1215–1217.
11.
BreitbachS, TugS, HelmigS, et al.Direct quantification of cell-free, circulating DNA from unpurified plasma. PLoS One, 2014; 9.
12.
NolanT, HandsRE, OgunkoladeW, et al.SPUD: a quantitative PCR assay for the detection of inhibitors in nucleic acid preparations. Anal Biochem, 2006; 351:308–310.
13.
De JonghR, VrankenJ, VundelinckxG, et al.The effects of anticoagulation and processing on assays of IL-6, sIL-6R, sIL-2R and soluble transferrin receptor. Cytokine, 1997; 9:696–701.
14.
LengelleJ, PanopoulosE, BetsouF. Soluble CD40 ligand as a biomarker for storage-related preanalytic variations of human serum. Cytokine, 2008; 44:275–282.
15.
KorseCM, HoldenriederS, ZhiXY, et al.Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China. Clin Chim Acta, 2015; 438:388–395.
16.
TrezziJ-P, BullaA, BelloraC, et al.LacaScore: a novel plasma sample quality control tool based on ascorbic acid and lactic acid levels. Metabolomics, 2016; in press.
17.
KamlageB, MaldonadoSG, BethanB, et al.Quality markers addressing preanalytical variations of blood and plasma processing identified by broad and targeted metabolite profiling. Clin Chem, 2014; 60:399–412.
18.
YiJ, KimC, GelfandCA. Inhibition of intrinsic proteolytic activities moderates preanalytical variability and instability of human plasma. J Proteome Res, 2007; 6:1768–1781.
19.
MarshallJ, KupchakP, ZhuW, et al.Processing of serum proteins underlies the mass spectral fingerprinting of myocardial infarction. J Proteome Res, 2003; 2:361–372.
20.
ChongBH, MurrayB, BerndtMC, et al.Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood, 1994; 83:1535–1541.
CarlebjorkG, BlombackM, AkerblomO. Improvement of plasma quality as raw material for factor VIII:C concentrates. Storage of whole blood and plasma and interindividual plasma levels of fibrinopeptide A. Vox Sang, 1983; 45:233–242.
23.
BetsouF, RousselB, GuillaumeN, et al.Long-term stability of coagulation variables: protein S as a biomarker for preanalytical storage-related variations in human plasma. Thromb Haemost, 2009; 101:1172–1175.
24.
BergKJ, KristoffersenDT, DjoselandO, et al.Reference range of some enzymes and proteins in untimed overnight urine and their stability after freezing. Clin Chim Acta, 1998; 272:225–230.
25.
UchidaK, GotohA. Measurement of cystatin-C and creatinine in urine. Clin Chim Acta, 2002; 323:121–128.
26.
PoulsenK, BahlJM, TanassiJT, et al.Characterization and stability of transthyretin isoforms in cerebrospinal fluid examined by immunoprecipitation and high-resolution mass spectrometry of intact protein. Methods, 2012; 56:284–292.
27.
HanssonSF, SimonsenAH, ZetterbergH, et al.Cystatin C in cerebrospinal fluid and multiple sclerosis. Ann Neurol, 2007; 62:193–196; discussion 205.
28.
GrecoV, PieragostinoD, PirasC, et al.Direct analytical sample quality assessment for biomarker investigation: qualifying cerebrospinal fluid samples. Proteomics, 2014; 14:1954–1962.
29.
TibbleJA, BjarnasonI. Fecal calprotectin as an index of intestinal inflammation. Drugs Today (Barc), 2001; 37:85–96.
30.
EhrichM, ZollS, SurS, et al.A new method for accurate assessment of DNA quality after bisulfite treatment. Nucleic Acids Res, 2007; 35:e29.
31.
VermeulenJ, De PreterK, LefeverS, et al.Measurable impact of RNA quality on gene expression results from quantitative PCR. Nucleic Acids Res, 2011; 39:e63.
32.
DebeyS, SchoenbeckU, HellmichM, et al.Comparison of different isolation techniques prior gene expression profiling of blood derived cells: impact on physiological responses, on overall expression and the role of different cell types. Pharmacogenomics J, 2004; 4:193–207.
33.
BenitaY, KikuchiH, SmithAD, et al.An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res, 2009; 37:4587–4602.
PinhelIF, MacneillFA, HillsMJ, et al.Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res, 2010; 12:R76.
36.
MasoodS, von WasielewskiR, MengelM, et al.Influence of fixation, antibody clones, and signal amplification on steroid receptor analysis. Breast J, 1998; 4:33–40.
37.
Yildiz-AktasIZ, DabbsDJ, BhargavaR. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol, 2012; 25:1098–1105.
38.
NeumeisterVM, ParisiF, EnglandAM, et al.A tissue quality index: an intrinsic control for measurement of effects of preanalytical variables on FFPE tissue. Lab Invest, 2014; 94:467–474.
39.
SkoldK, SvenssonM, NorrmanM, et al.The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: stathmin 2–20 and peptides as sample quality indicators. Proteomics, 2007; 7:4445–4456.
40.
FerrerI, SantpereG, ArzbergerT, et al.Brain protein preservation largely depends on the postmortem storage temperature: implications for study of proteins in human neurologic diseases and management of brain banks: a BrainNet Europe Study. J Neuropathol Exp Neurol, 2007; 66:35–46.
41.
ScholzB, SkoldK, KultimaK, et al.Impact of temperature dependent sampling procedures in proteomics and peptidomics—a characterization of the liver and pancreas post mortem degradome. Mol Cell Proteomics, 2011; 10.
42.
SerizawaM, YokotaT, HosokawaA, et al.The efficacy of uracil DNA glycosylase pretreatment in amplicon-based massively parallel sequencing with DNA extracted from archived formalin-fixed paraffin-embedded esophageal cancer tissues. Cancer Genet, 2015; 208:415–427.
43.
van BeersEH, JoosseSA, LigtenbergMJ, et al.A multiplex PCR predictor for aCGH success of FFPE samples. Br J Cancer, 2006; 94:333–337.
44.
WangF, WangL, BriggsC, et al.DNA degradation test predicts success in whole-genome amplification from diverse clinical samples. J Mol Diagn, 2007; 9:441–451.
45.
GajadharAS, JohnsonH, SlebosRJ, et al.Phosphotyrosine signaling analysis in human tumors is confounded by systemic ischemia-driven artifacts and intra-specimen heterogeneity. Cancer Res, 2015; 75:1495–1503.
46.
LiJ, KilC, ConsidineK, et al.Intrinsic indicators for specimen degradation. Lab Invest, 2013; 93:242–253.
47.
DirksWG, DrexlerHG. Authentication of scientific human cell lines: easy-to-use DNA fingerprinting. Methods Mol Biol, 2005; 290:35–50.
48.
JeonJP, NamHY, ShimSM, et al.Sustained viral activity of Epstein–Barr virus contributes to cellular immortalization of lymphoblastoid cell lines. Mol Cells, 2009; 27:143–148.
49.
LowesLE, HedleyBD, KeeneyM, et al.User-defined protein marker assay development for characterization of circulating tumor cells using the CellSearch® system. Cytometry A, 2012; 81:983–995.
50.
McKennaKC, BeattyKM, Vicetti MiguelR, et al.Delayed processing of blood increases the frequency of activated CD11b+ CD15+ granulocytes which inhibit T cell function. J Immunol Methods, 2009; 341:68–75.
51.
EvensonD, JostL. Sperm chromatin structure assay is useful for fertility assessment. Methods Cell Sci, 2000; 22:169–189.
52.
Bennett-GuerreroE, VeldmanTH, DoctorA, et al.Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A, 2007; 104:17063–17068.
53.
HolmeS, SweeneyJD, SawyerS, et al.The expression of p-selectin during collection, processing, and storage of platelet concentrates: relationship to loss of in vivo viability. Transfusion, 1997; 37:12–17.
